BSBiman Saikia

Biman Saikia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Biman Saikia has a total of 170 co-authors. Here are the top co-authors by number of shared publications:

  • Ranjana Walker Minz

    Department of Immunopathology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India

    14 shared publications
  • Amit Rawat

    Pediatric Allergy and Immunology Unit, Department of Pediatrics, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India

    11 shared publications
  • Surjit Singh

    Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India

    9 shared publications
  • Deepti Suri

    Pediatric Allergy Immunology Unit, Department of Pediatrics, https://ror.org/009nfym65Postgraduate Institute of Medical Education & Research, Chandigarh, India

    7 shared publications
  • Deepti Suri

    Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India

    5 shared publications
  • Shobha Sehgal

    Department of Immunopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

    5 shared publications

Latest Publications

  • Antineutrophil Cytoplasmic Antibodies: Integrating History, Pathogenesis, and Modern Diagnostics

    by Aravind Radhakrishnan, Biman Saikia, Aman Sharma, Seema Chhabra

    Antineutrophil cytoplasmic antibodies (ANCA) define a distinct group of small‐vessel vasculitides collectively termed ANCA‐associated vasculitis (AAV). Since their initial recognition as immunofluorescence patterns, ANCA have evolved into well‐characterized pathogenic autoantibodies directed primarily against proteinase 3 (PR3) and myeloperoxidase (MPO). This review integrates the historical evolution of ANCA discovery with current understanding of disease pathogenesis and contemporary diagnostic practice. We summarize key biological mechanisms underlying AAV, including genetic susceptibility, epigenetic dysregulation, neutrophil priming, complement activation via the alternative pathway, and neutrophil extracellular trap formation, which together drive endothelial injury and necrotizing vasculitis. Recognition of PR3 ANCA and MPO ANCA as pathogenic entities has reshaped disease classification and supports the concept of biologically distinct disease subsets. In parallel, laboratory diagnostics have undergone a major paradigm shift. We critically review the transition from indirect immunofluorescence‐first algorithms to immunoassay‐first strategies endorsed by the 2017 revised international consensus, highlighting the improved diagnostic performance of contemporary antigen‐specific immunoassays. The roles of automated immunofluorescence, biochip mosaic platforms, and multiparametric testing are discussed within harmonized diagnostic workflows. Emphasis is placed on strict clinical gating, quantitative antibody interpretation, and likelihood ratio‐based reporting to enhance diagnostic accuracy and reduce false‐positive results. By integrating historical, biological, and diagnostic perspectives, this review provides a practical reference framework for evidence‐based ANCA testing and interpretation in clinical practice.

  • Open Access

    Successful coil occlusion of intracranial aneurysm in a child with STAT3 hyper IgE syndrome

    by Archan Sil, Chirag K. Ahuja, Pandiarajan Vignesh, Amit Rawat, Biman Saikia

    A novel heterozygous STAT3 variant (p.Phe710Ser) was identified in an adolescent with hyper IgE syndrome and an intracranial aneurysm. Successful nonsurgical coil occlusion underscores the importance of vascular screening and the feasibility of interventional radiology in HIES.

  • Evolution of India’s National teleconsultation platform e-Sanjeevani: A comparative analysis of versions 2.0 and 1.0, with a preliminary report from the state of Haryana

    by Richa Gupta, Mandula Phani Priya, Nabaneeta Dash, Aruna Singh, Liza Das, Atul Arora, Priyadarshini Sahu, Kanya Rani Vashisht, Anil Eragam, Paramvir Singh, et al.


  • Open Access

    Unraveling the unphosphorylated STAT3–unphosphorylated NF-κB pathway in loss of function STAT3 Hyper IgE syndrome

    by Adil Karim, Rashi Garg, Biman Saikia, Abha Tiwari, Smrity Sahu, Mehak Malhotra, Ranjana W. Minz, Amit Rawat, Surjit Singh, Deepti Suri

    Background: Patients with loss of function signal transducer and activator of transcription 3-related Hyper IgE Syndrome (LOF STAT3 HIES) present with recurrent staphylococcal skin and pulmonary infections along with the elevated serum IgE levels, eczematous rashes, and skeletal and facial abnormalities. Defective STAT3 signaling results in reduced Th17 cells and an impaired IL-17/IL-22 response primarily due to a compromised canonical Janus kinase-signal transducer and activator of transcription (JAK–STAT) pathway that involves STAT3 phosphorylation, dimerization, nuclear translocation, and gene transcription. The non-canonical pathway involving unphosphorylated STAT3 and its role in disease pathogenesis, however, is unexplored in HIES.Objective: This study aims to elucidate the role of unphosphorylated STAT3–unphosphorylated NF-κB (uSTAT3–uNF-κB) activation pathway in LOF STAT3 HIES patients.Methodology: The mRNA expression of downstream molecules of unphosphorylated STAT3–unphosphorylated NF-κB pathway was studied in five LOF STAT3 HIES patients and transfected STAT3 mutants post-IL-6 stimulation. Immunoprecipitation assays were performed to assess the binding of STAT3 and NF-κB to RANTES promoter.Results: A reduced expression of the downstream signaling molecules of the uSTAT3–uNF-κB complex pathway, viz., RANTES, STAT3, IL-6, IL-8, ICAM1, IL-8, ZFP36L2, CSF1, MRAS, and SOCS3, in LOF STAT3 HIES patients as well as the different STAT3 mutant plasmids was observed. Immunoprecipitation studies showed a reduced interaction of STAT3 and NF-κB to RANTES in HIES patients.Conclusion: The reduced expression of downstream signaling molecules, specially RANTES and STAT3, confirmed the impaired uSTAT3–uNF-κB pathway in STAT3 LOF HIES. Decreased levels of RANTES and STAT3 could be a significant component in the disease pathogenesis of Hyper IgE Syndrome.


  • An Indian Family with Autosomal Dominant Hyper-IgE Syndrome Due to IL6ST Defect

    by Suprit Basu, Shubham Goel, Amit Rawat, Pandiarajan Vignesh, Biman Saikia


  • Open Access

    Management of hereditary angioedema in resource-constrained settings: A consensus statement from Indian subcontinent

    by Ankur Kumar Jindal, Archan Sil, Ridhima Aggarwal, Keshavamurthy Vinay, Anuradha Bishnoi, Deepti Suri, Amit Rawat, Muthu Sendhil Kumaran, Biman Saikia, Rashmi Sarkar, et al.

    Hereditary angioedema (HAE) is an uncommon disorder characterized clinically by recurrent episodes of nonitchy subcutaneous and/or submucosal swellings. The estimated prevalence of HAE is ~ 1: 10,000 to 1: 50,000. There are no prevalence data from India, however, estimates suggest that there are 27,000 to 135,000 patients with HAE in India at present. The majority of these, however, remain undiagnosed. Replacement of plasma-derived or recombinant C1-esterase inhibitor (C1-INH) protein, administered intravenously, is the treatment of choice during the management of acute episodes of angioedema (i.e., “on-demand treatment”) and is also useful for short-term prophylaxis (STP) and long-term prophylaxis (LTP). This has been found to be effective and safe even in young children and during pregnancy. Until recently, none of the first-line treatment options were available for “on-demand treatment,” STP or LTP in India. As a result, physicians had to use fresh frozen plasma for both “on-demand treatment” and STP. For LTP, attenuated androgens (danazol or stanozolol) and/or tranexamic acid were commonly used. These drugs have been reported to be useful for LTP but are associated with a significant risk of adverse effects. Intravenous pd-C1-INH, the first-line treatment option, is now available in India. However, because there is no universal health insurance, access to pd-C1-INH is a significant challenge. HAE Society of India has developed these consensus guidelines for India and other resource-constrained settings where plasma-derived C1-INH therapy is the only available first-line treatment option for the management of HAE and diagnostic facilities are limited. These guidelines have been developed because it may not be possible for all patients to access the recommended therapy and at the recommended doses as suggested by the international guidelines. Moreover, it may not be feasible to follow the evaluation algorithm suggested by the international guidelines.


  • Open Access

    Human STAT3 variants underlie autosomal dominant hyper-IgE syndrome by negative dominance

    by Takaki Asano, Joëlle Khourieh, Peng Zhang, Franck Rapaport, András N. Spaan, Juan Li, Wei-Te Lei, Simon J. Pelham, David Hum, Maya Chrabieh, et al.

    Most patients with autosomal dominant hyper-IgE syndrome (AD-HIES) carry rare heterozygous STAT3 variants. Only six of the 135 in-frame variants reported have been experimentally shown to be dominant negative (DN), and it has been recently suggested that eight out-of-frame variants operate by haploinsufficiency. We experimentally tested these 143 variants, 7 novel out-of-frame variants found in HIES patients, and other STAT3 variants from the general population. Strikingly, all 15 out-of-frame variants were DN via their encoded (1) truncated proteins, (2) neoproteins generated from a translation reinitiation codon, and (3) isoforms from alternative transcripts or a combination thereof. Moreover, 128 of the 135 in-frame variants (95%) were also DN. The patients carrying the seven non-DN STAT3 in-frame variants have not been studied for other genetic etiologies. Finally, none of the variants from the general population tested, including an out-of-frame variant, were DN. Overall, our findings show that heterozygous STAT3 variants, whether in or out of frame, underlie AD-HIES through negative dominance rather than haploinsufficiency.


  • Open Access

    Clinical Profile of Hyper-IgE Syndrome in India

    by Biman Saikia, Amit Rawat, Ranjana W. Minz, Deepti Suri, Vignesh Pandiarajan, Ankur Jindal, Smrity Sahu, Adil Karim, Mukesh Desai, Prasad D. Taur, et al.

    Introduction:Hyper-IgE Syndrome (HIES) is a rare inborn error of immunity (IEI) characterized by a constellation of symptoms related to susceptibility toStaphylococcalskin and pulmonary infections, eczema, raised serum IgE (>2,000 IU/ml), craniofacial anomalies, and recurrent bone fractures. Data on HIES from the Indian subcontinent is scarce and restricted to small case series and case reports. This is the first compilation of national data on HIES.Materials and Methods:A total 103 cases clinically diagnosed and treated as HIES were analyzed from nine centers. Cases with clinical and/or molecular diagnosis of DOCK8 deficiency were not included. Patients were divided into two groups: group I for whom a heterozygous rare variant of STAT3 was identified, and group II, with clinical features similar to those of AD STAT3 deficiency, but without any genetic diagnosis.Results:Genetic diagnosis was available in 27 patients (26.2%) and all harbored rare variants in the STAT3 gene. Majority of these STAT3 HIES patients presented with recurrent skin abscesses (77.7%) or pneumonia (62.9%) or both (59.2%). Other features included eczema (37%), candidiasis (55.5%), facial dysmorphism (55.5%), recurrent fractures (11.1%), and retained primary teeth (7.4%).Mycobacterialinfections were seen in a significant 18.5%. Mortality was seen in three subjects (11.1%). A similar trend in the clinical presentation was observed when all the 103 patients were analyzed together. Twenty percent of patients without a rare variant in the STAT3 gene had an NIH score of ≥40, whereas, 51.9% of STAT3 HIES subjects had scores below the cut off of ≥40. TH17 cell numbers were low in 10/11 (90.9%) STAT3 HIES tested. Rare variants observed were 8 in exon 21; 8 in exon 13; 3 in exon 10; 2 in exon 15, and one each in exon 6, 16, 17, 19, 22, and splice site downstream of exon 12. Seven variants were novel and included F174S, N567D, L404Sfs*8, G419 =, M329K, T714I, R518X, and a splice site variant downstream of exon 12.Conclusions:The report includes seven novel STAT3 variants, including a rare linker domain nonsense variant and a CC domain variant.Mycobacterialdiseases were more frequent, compared to western literature.


  • Metabolic Syndrome and Its Effects on Cartilage Degeneration vs Regeneration: A Pilot Study Using Osteoarthritis Biomarkers

    by Rajath Siddaramanna Onkarappa, Devendra Kumar Chauhan, Biman Saikia, Adil Karim, Rajendra Kumar Kanojia

    Background Osteoarthritis (OA) of the knee is one of the leading causes of disability characterized by degeneration of hyaline cartilage combined with reparative processes. Its strong association with metabolic syndrome is postulated to be due to both mechanical and biochemical factors. Our study aims to study differential effect of metabolic risk factors on cartilage degeneration and regeneration at biomarker level. Design After screening 281 patients presenting with knee pain, 41 patients who met the selection criteria were included and were divided into metabolic (MetS) OA and non-metabolic (Non-MetS) OA phenotypes using National Cholesterol Education Programme—Adult Treatment Panel—III (NCEP-ATP-III) criteria for metabolic syndrome. Serum Cartilage Oligomeric Matrix Protein (COMP) and Procollagen type IIA N terminal Propeptide (PIIANP) levels were used as tools to assess cartilage degeneration and regeneration, respectively. Results 22 among 41 patients (53.66%) had metabolic syndrome. Covariates like age, gender, Kellgren Lawrence (KL) grades were comparable in both groups. MetS-OA group showed significant increase in serum COMP levels (p = 0.03) with no significant effect on serum PIIANP levels (p = 0.46). Hypertriglyceridemia showed independent association with both cartilage anabolism (p = 0.03) and catabolism (p = 0.03). Conclusion Metabolic syndrome, though has no effect on cartilage regeneration tends to shift cartilage homeostasis towards degeneration with hypertriglyceridemia showing significant independent effect on cartilage metabolism.